Showing results (121-130 of 4,234) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|March 25, 2021
Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathwaysDenise Cecil, Kyong Hwa Park, Benjamin Curtis, et al.Journal for Immunotherapy of Cancer|March 8, 2021
Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancerAnna Wilkins, Elisa Fontana, Gift Nyamundanda, et al.Journal for Immunotherapy of Cancer|March 10, 2021
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapyVeronica Olivo Pimentel, Damiënne Marcus, Alexander Ma van der Wiel, et al.Journal for Immunotherapy of Cancer|March 10, 2021
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancerDavide Melisi, Do-Youn Oh, Antoine Hollebecque, et al.Journal for Immunotherapy of Cancer|October 21, 2022
Combining precision oncology and immunotherapy by targeting the MALT1 proteaseThorsten R Mempel, Daniel KrappmannJournal for Immunotherapy of Cancer|November 1, 2022
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumorsMarina Natoli, Klas Hatje, Pratiksha Gulati, et al.Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.Journal for Immunotherapy of Cancer|October 25, 2022
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse eventsAlexander Coukos, Julien Vionnet, Michel Obeid, et al.Journal for Immunotherapy of Cancer|October 25, 2022
Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cellsShi Yong Neo, Xu Jing, Le Tong, et al.Journal for Immunotherapy of Cancer|October 5, 2022
CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 proteinMin Dong, Min Qian, Zhengyi RuanPageof 424